Table 3. Supplementary Table 2: Neurological adverse drug events suspected to be caused by Astra Zeneca vaccine use in COVID-19.
Broad heading | Specific adverse event | Non-serious n(%) (n=1,527) | Serious n(%) (n=1,224) | Total n(%) (n=2,751) |
Nervous System Disorder(N=2751) | Ageusia | 5(0.33) | 5(0.41) | 10(0.36) |
Allodynia | 2(0.13) | 1(0.08) | 3(0.11) | |
Amnesia | 1(0.07) | 0(0.00) | 1(0.04) | |
Anosmia | 1(0.07) | 4(0.330 | 5(0.18) | |
Aphasia | 0(0.00) | 2(0.16) | 2(0.07) | |
Balance disorder | 2(0.13) | 7(0.57) | 9(0.33) | |
Brain stem stroke | 0(0.00) | 1(0.08) | 1(0.04) | |
Burning sensation | 0(0.00) | 2(0.16) | 2(0.07) | |
Cerebrovascular accident | 0(0.00) | 3(0.25) | 3(0.11) | |
Cervicobrachial syndrome | 1(0.07) | 0(0.00) | 1(0.04) | |
Clumsiness | 0(0.00) | 1(0.08) | 1(0.04) | |
Cluster headache | 4(0.26) | 5(0.41) | 9(0.33) | |
Cognitive disorder | 1(0.07) | 1(0.08) | 2(0.07) | |
Coordination abnormal | 1(0.07) | 0(0.00) | 1(0.04) | |
Disturbance in attention | 2(0.13) | 4(0.33) | 6(0.22) | |
Dizziness | 180(11.79) | 154(12.58) | 334(12.14) | |
Dizziness postural | 11(0.72) | 1290.98) | 23(0.84) | |
Dysarthria | 0(0.00) | 1(0.08) | 1(0.04) | |
Dysgeusia | 23(1.51) | 11(0.90) | 34(1.24) | |
Dysstasia | 0(0.00) | 2(0.16) | 2(0.07) | |
Epilepsy | 0(0.00) | 2(0.16) | 2(0.07) | |
Facial paralysis | 2(0.13) | 1(0.08) | 3(0.11) |